The current study represents a subset analysis of quality-of-life (QOL) outcomes among patients treated on a phase 2 trial of de-escalated chemoradiation for human papillomavirus (HPV)-associated oropharyngeal cancer. METHODS: Eligibility included newly diagnosed, (American Joint Committee on Cancer, 7th edition) stage III or IV oropharyngeal squamous cell carcinoma, p16 positivity, age 18 years, and a Zubrod performance status of 0 to 1. Treatment was induction paclitaxel at a dose of 175 mg/m 2 and carboplatin at an area under the curve of 6 for 2 cycles followed by response-adapted, dose-reduced radiation of 54 Gy or 60 Gy with weekly concurrent paclitaxel at a dose of 30 mg/m 2 . The University of Washington Quality of Life (UW-QOL) and the Functional Assessment of Cancer Therapy-Head and Neck questionnaires were used to assess patient-reported QOL as a secondary endpoint. RESULTS: A total of 45 patients were registered, 40 of whom completed QOL surveys and were evaluable. Nadirs for overall UW-QOL and Functional Assessment of Cancer Therapy-Head and Neck scores were reached at 4 weeks after treatment but returned to baseline at 3 months. Nearly all functional indices returned to baseline levels by 6 to 9 months. The mean overall UW-QOL score was 71.6 at baseline compared with 70.8, 73.0, 83.3, and 81.1, respectively, at 3 months, 6 months, 1 year, and 2 years after therapy. The percentage of patients rating their overall QOL as "very good" or "outstanding" at 6 months, 1 year, and 2 years using the UW-QOL was 50%, 77%, and 84%, respectively. CONCLUSIONS: This de-escalation regimen achieved QOL outcomes that were favorable compared with historical controls. These results serve as powerful evidence that ongoing de-escalation efforts lead to tangible gains in function and QOL. Cancer 2018;124:521-9.
INTRODUCTION
Although concurrent chemoradiation represents a potentially curative therapeutic option for patients with locally advanced squamous cell carcinoma of the head and neck, it historically has been associated with significant long-term toxicity. 1, 2 Common side effects include swallowing dysfunction, fatigue, xerostomia, and salivary changes among others. Given the increasing recognition of the influence that quality of life (QOL) has on survivorship for patients with head and neck cancer, incorporating this endpoint into the evaluation of efficacy is becoming more important to refine treatment strategies. 3 This is particularly relevant because survival rates continue to improve for this disease and patients are living longer. Although modern techniques with intensity-modulated radiotherapy (IMRT) have been associated with improvements in patient-reported QOL, the incidence of treatment-related morbidity remains high. 4 For example, the dose threshold to cause dysphagia due to pharyngeal constrictor muscle or larynx dysfunction likely rests at a dose of 60 Gy. [5] [6] [7] [8] This threshold may be challenging to avoid in some clinical scenarios when macroscopic disease rests immediately adjacent to these structures and the maximum radiation dose level is 70 Gy. In addition, multiple studies have noted that even with modern treatment techniques, QOL recovery often takes >1 year. [9] [10] [11] [12] As such, lower maximum dose levels may improve the morbidity profile of treatment.
It now is well established that patients with oropharyngeal squamous cell carcinoma related to the human papillomavirus (HPV) have both a more robust response to treatment and an improved overall prognosis compared with those whose tumors are not related to HPV. [13] [14] [15] Due to an abundance of preclinical and clinical data that have demonstrated that HPVpositive tumors are exquisitely radiosensitive, interest has arisen focusing on the attenuation of treatment regimens with the aim of improving QOL while maintaining rates of disease control. [16] [17] [18] We previously reported the results of a phase 2 de-escalation trial evaluating the use of reduced doses of radiation and demonstrated excellent rates of progressionfree and overall survival. 19 The objective of the current follow-up report is to document trends in QOL for patients treated on this prospective clinical trial.
MATERIALS AND METHODS
From October 2012 to March 2015, a total of 45 patients with HPV-positive oropharyngeal carcinoma were enrolled on a phase 2 trial of de-escalated chemoradiation conducted jointly between the schools of medicine at the University of California at Davis and the University of California at Los Angeles. This subset analysis was designed to report on the secondary endpoint of QOL and was comprised of 40 subjects who completed QOL data sets and who were without evidence of disease at the time of their most recent follow-up. Eligible participants were aged 18 years with a Zubrod performance status of 0 to 1 and a histological diagnosis of newly diagnosed, (American Joint Committee on Cancer (AJCC), 7th edition) stage III or IV, HPV-associated squamous cell carcinoma arising from the oropharynx. Smoking history was not used as a criterion for eligibility. HPV positivity was defined as tumors that were p16 positive by immunohistochemistry. Baseline patient characteristics are reported in Table 1 . The protocol of the study was approved by the Institutional Review Boards of both universities, and all study participants provided written informed consent. The trial is registered with ClinicalTrials.gov (ClinicalTrials.gov identifiers NCT02048020 and NCT01716195) and opened separately at the schools of medicine of the University of California at Davis and the University of California at Los Angeles, respectively, before the data were centrally combined for aggregate analysis.
Two cycles of induction chemotherapy (paclitaxel at a dose of 175 mg/m 2 infused over 3 hours followed by carboplatin at an area under the curve of 6 as a 30-minute infusion) were administered to all patients primarily as a means to select patients with HPV-positive oropharyngeal carcinoma, who may benefit from significant deescalations in the radiation dose. At least 2 weeks after the completion of induction chemotherapy, concurrent chemoradiation was initiated using single-agent paclitaxel infused at a dose of 30 mg/m 2 over at least 1 hour given weekly with daily radiation for 5 total cycles. The radiation dose was determined by the clinical response to induction chemotherapy using Response Evaluation Criteria In Solid Tumors (RECIST). 20 For patients who achieved a complete response or partial response, the total prescribed dose to the primary tumor and involved lymph nodes was 54 Gy in 27 fractions. All other patients were classified as having a minor response and received 60 Gy in 30 fractions. IMRT was mandated.
QOL assessment was performed using 2 previously validated surveys administered at the time of registration 21 The UW-QOL consists of 12 domains pertaining to QOL in the categories of pain, appearance, activity, recreation, swallowing, chewing, speech, shoulder function, taste, saliva, mood, and anxiety. A score of 0 indicates very poor or no functional capacity with regard to that domain whereas a score of 100 indicates no disability in that domain. In the final part of the UW-QOL, patients were asked general questions focused on QOL. This segment was scored with 0 indicating very poor QOL and 100 indicating outstanding QOL, with a range of scores as integer values in between. The Functional Assessment of Cancer TherapyHead and Neck scale (FACT-H&N) is a validated, multidimensional, self-reported QOL instrument specifically designed for use with patients with head and neck cancer. 22 It consists of 27 core items that assess patient function in 4 domains (physical, social/family, emotional, and functional well-being), which is supplemented further by 12 site-specific items to assess for head and neck-related symptoms. Each item is rated on a Likert-type scale from 0 to 4, with higher scores representing better QOL, and then combined to produce subscale scores for each domain as well as a global QOL score. The FACTGeneral (FACT-G) subscore (encompassing physical, social, emotional, and functional well-being subscales) and FACT-H&N subscore (encompassing the head and neck-specific domain alone) also were determined. QOL data were presented using descriptive statistics. Any patient with a missing survey was excluded in the data set for that particular time point.
Statistical Analysis
Differences in percentages among subsets were evaluated using the Fisher exact test. A 2-tailed Student t test was used to compare QOL scores at time points after treatment with baseline values. Logistical regression was performed to evaluate whether pretreatment or treatment factors, including increasing age, smoking history (10 pack-years vs > 10 pack-years), alcohol history (none to moderate vs heavy), sex, T classification, N classification, site of the primary tumor, and radiation dose, were associated with UW-QOL and FACT-H&N scores at both 6 months and 12 months after treatment. A P of .05 was considered to indicate statistical significance.
RESULTS

UW-QOL Analysis
The baseline, 6-month, 12-month, 18-month, and 24-month posttreatment UW-QOL survey completion rates were 90%, 53%, 75%, 65%, and 50%, respectively. Supporting Information Table S1 outlines UW-QOL scores for overall, health-related, and function-related QOL at various time points compared with baseline. The mean overall and health-related QOL scores as determined by the UW-QOL were 71.6 (range, 40-100) and 69.7 (range, 20-100), respectively, at baseline. As illustrated in Figure  1 , the nadirs were reached at approximately 4 weeks after treatment for both measures. Supporting Information Table S2 outlines the percentage change in each of the UW-QOL domains from baseline values. The mean overall QOL values were 70.8, 73.0, 83.3, and 81.1, respectively, at 3 months, 6 months, 1 year, and 2 years after the completion of treatment. At 3 months, 12 of 37 patients (32%) continued to experience a decline in their overall QOL scores compared with baseline. However, no significant decrease in the mean overall QOL score compared with baseline was found to exist at 3 months (70.8 vs 71.6; P 5 .86) or at any time point thereafter. By 12 months after therapy, the mean overall QOL score (83.3) actually exceeded the value at baseline (P 5 .006. At 6 months, 1 year, and 2 years after treatment, the percentage of patients reporting a decline from baseline was 40%, 13%, and 32%, respectively. For health-related QOL, the mean scores at 3 months, 6 months, 1 year, and 2 years were 63.2, 71.0, 79.3, and 74.7, respectively. The corresponding percentage of patients reporting a decline in their health-related QOL compared with baseline was 38%, 30%, 27%, and 26%, respectively. Figure 2 illustrates the individual domain scores for the UW-QOL survey over time. Domain scores for taste (P<.0001) and salivary function (P<.0001) remained approximately 49% and 51% lower in magnitude, respectively, compared with baseline when assessed at 6 months after treatment (see Supporting Information Tables S1  and S2 ). Median QOL scores related to swallowing returned to baseline at 15 months (P 5 .28). Although taste and salivary function were more slow to recover, continued improvement was observed even from the 18-month to 24-month time points. The composite UW-QOL score, averaging all 12 domains, returned to baseline at approximately 9 months after treatment (P 5 .38).
By 3 months, there was no difference with regard to how patients rated their health-related (P 5 .11) and overall (P 5 .86) QOL over the past 7 days compared with baseline for both. The percentages of patients rating their overall QOL as "very good" or "outstanding" at 6 months, 1 year, and 2 years were 50%, 77%, and 84%, respectively. The percentages of patients rating their overall QOL as "good" during these time points were 25%, 17%, and 11%, respectively. With respect to health-related QOL, approximately 50%, 77%, and 63% of patients, respectively, rated their health-related QOL as "very good" or "outstanding" at 6 months, 1 year, and 2 years.
FACT-H&N Analysis
The baseline, 6-month, 12-month, 18-month, and 24-month posttreatment FACT-H&N survey completion rates were 78%, 40%, 53%, 43%, and 35%, respectively. The FACT-H&N QOL survey results are outlined in Table 2 . The mean total score, FACT-G subscore, and head and neck subscore from the FACT-H&N were 120.4, 88.3, and 32.1, respectively, at baseline. At 4 weeks after completion of the protocol therapy, the corresponding values were 97.0, 77.1, and 19.9, respectively, each of which was significantly depressed from baseline and representing the nadirs during the posttreatment period (P<.05 for all). However, at 3 months after treatment, the mean total score and FACT-G subscore were 112.2 and 87.9, respectively, which represented almost complete return to baseline. The mean FACT-H&N subscore was 24.9 at this time point, which still was significantly lower than its baseline value (P<.001). At approximately 6 months, the mean total score and FACT-G subscore were 118.8 and 91.5, respectively, which did not differ significantly from baseline (P>.05 for both). The mean FACT-H&N subscore was 27.4 at this time point, which continued to be significantly lower compared with baseline (P 5 .0012). At 9 months, the mean FACT-H&N subscore had increased to 26.1, which did not differ significantly from baseline for the evaluable patients (P 5 .099). The mean total score, FACT-G subscore, and FACT-H&N subscore were 126.5, 95.0, and 31.4, respectively, at 12 months. The mean total score, FACT-G subscore, and FACT-H&N subscore were 123.0, 93.6, and 29.4, respectively, at 24 months.
Factors Impacting QOL
On univariate analysis, none of the pretreatment or treatment-related factors were found to be predictive for overall QOL at 6 months or 12 months by either reporting instrument (P>.05 for both). Trends were identified that suggested that a base-of-tongue primary site predicted for a worse UW-QOL swallowing domain at 12 months (odds ratio, 3.84; 95% confidence interval, 0.83-1.7.71 [P 5 .08]) and that advancing age was predictive of a worse FACT-H&N subscale score at 6 months (odds ratio, 1.18; 95% confidence interval, 0.99-1.41 [P 5 .07]). None of the other analyzed factors were found to be associated with the UW-QOL scores related to health-related QOL or any of the functional domains as well as the FACT-H&N and FACT-G subscale scores at 6 months, 12 months, or 24 months (P>.05 for all).
As shown in Figure 3 , no difference was observed between patients stratified to the 54-Gy treatment arm and those stratified to the 60-Gy treatment arm at any time point with respect to the overall UW-QOL score except at 4 weeks when the latter cohort was found to have a significantly lower nadir in QOL compared with the former cohort (66.7 vs 44.6; P 5 .04). FACT-H&N scores paralleled these findings with a statistically significant differential nadir between the 54-Gy and 60-Gy treatment arms observed at 4 weeks (104.0 vs 87.1; P 5 .03).
DISCUSSION
The current analysis of prospectively acquired QOL outcome data is the first to our knowledge to illustrate how reduced doses of radiation might influence survivorship for patients with locally advanced, HPV-positive oropharyngeal carcinoma treated with chemoradiation. The findings of the current study provide powerful evidence that de-escalation strategies can indeed translate into tangible benefits for this population with respect to both physical and psychosocial functioning, leading to improvements in QOL compared with historical controls. These results serve as validation for approaches investigating deescalation and attest to the feasibility of enhancing QOL for those individuals historically treated with regimens associated with significant toxicity.
Most prominently, the current study findings demonstrating a return to baseline as early as 3 months after the completion of de-escalated chemoradiation for many of the QOL indices analyzed strongly suggest that functional recovery occurs more briskly and robustly than typically observed for patients treated with conventional regimens. As important, overall QOL, as determined by both the UW-QOL and FACT-H&N instruments, was maintained thereafter at baseline levels through 2 years after treatment. These data strongly suggest that deescalated chemoradiation accomplished its goal of reducing treatment-related morbidity and preserving long-term QOL in patients with HPV-associated oropharyngeal carcinoma.
Although nadirs in subjective functioning generally were reached at 4 weeks after therapy, a gradual return to baseline in all domains was observed as expected. These were largely consistent with data published regarding patients treated with full-dose radiation regimens with the caveat that recovery clearly occurred earlier. [9] [10] [11] [12] 23 Surprisingly, mood and anxiety stabilized to levels above baseline even by time points within the acute toxicity phase, suggesting that the psychological consequences of treatment were not as profound as those typically observed among patients treated with conventional regimens. For example, in a longitudinal study, Chen et al found that approximately 85% of patients undergoing full-dose radiation experienced significant increases in self-reported depressive symptoms from before radiation was initiated to its completion. 24 The most encouraging finding from the current analysis was that overall UW-QOL and FACT-H&N scores returned nearly to baseline just 3 months after treatment for essentially all patients. The most direct comparison is to data from Vainshtein et al demonstrating that the majority of patients treated to standard radiation doses did not experience QOL recovery until at least 1 year after treatment. 9 In a prospective study of 111 patients treated with IMRT for head and neck cancer, Tribius et al also demonstrated that QOL took 1 year to recover on average and that residual deficits persisted even at that point in the majority of subjects. 10 Recently published subset analyses of large prospective trials conducted by the Radiation Therapy Oncology Group by Xiao et al and Truong et al evaluating patients treated with chemoradiation to 70 Gy similarly demonstrated that patients with HPV-associated disease experienced precipitous declines in their QOL with a return to pretreatment baseline not occurring until at least 1 year after therapy in most patients. 11, 12 Indeed, results from the Radiation Therapy Oncology Group 0522 trial using a concurrent chemoradiation backbone of cisplatin with 70 Gy of radiation with or without cetuximab demonstrated that at 1 year, continued differences in FACT-H&N scores persisted for all subjects, 12 which was in stark contrast to our findings among patients treated with de-escalation. Ringash et al similarly demonstrated that QOL as measured by the FACT-H&N was slow to recover among patients treated with chemoradiation on a prospective trial conducted by the TransTasmanian Oncology Group. 23 Chen et al also reported an overall UW-QOL score of 67.5 at 1 year after therapy among 84 patients treated with IMRT to standard doses, representing a 23% lower score than reported in the current series. 4 It is interesting to note that in that series, a significantly greater percentage of patients had yet to return to their QOL baselines compared with the subjects in the current study.
Of course, not all subjects returned to their baseline overall QOL score, with 32% reporting a decline from baseline at 2 years according to the UW-QOL. This may be related to several domains in the UW-QOL never returning to baseline after treatment. For example, the domain scores for taste (P<.0001) and salivary function (P<.0001) remained significantly lower than baseline 2 years after treatment, although continued improvement was noted in both from the 18-month to 24-month time points. Although the swallowing domain initially recovered, it subsequently began to decline slightly at 24 months. Therefore, although overall QOL metrics appear very encouraging with dose-de-escalated chemoradiation, it is worth noting that domains related to speech and swallowing still may be affected long term. It is interesting to note that all of these subjects participated in a clinical trial for which the main interest in participation was the potential for improved salivary and swallowing function in the long term from radiation dose de-escalation. As such, any longterm change in the function of these domains, however small, may have been more unfavorably viewed by the study population compared with patients treated with fulldose chemoradiation because of differing expectations.
The rationale for de-escalation lies in the assumption that relationships exist between increasing the radiation dose to certain anatomical organs and the probability of clinical toxicity. It is interesting to note that the doseresponse threshold (ie, the steep part of the sigmoidal curve) for many side effects rests between 50 Gy and 70 Gy, suggesting that shifting a patient from one side of the normal tissue complication probability curve slope to the other theoretically will improve QOL. For example, data have shown that the dose to such structures as the pharyngeal constrictor muscles, cricopharyngeal inlet, and larynx is of critical importance in predicting toxicity from chemoradiation and that the threshold for radiation-induced long-term dysphagia likely exists at approximately 55 to 60 Gy. [5] [6] [7] [8] The results of de-escalation efforts such as ours thus are particularly relevant because it is well established that concurrent chemoradiation for head and neck cancer has eclipsed the limits of acceptable long-term toxicity. As important, the current study data demonstrating improvements in QOL among patients with HPVpositive oropharyngeal cancer provide important reassurances legitimizing the premise of de-escalation.
Although direct comparisons are potentially confounded by differences in patient and disease characteristics, we believe it nonetheless is apparent that the QOL outcomes reported herein are among the most encouraging ever observed for any group of patients treated for head and neck cancer. However, we acknowledge that quantifying QOL is difficult and can be complicated by non-treatment-related factors, including socioeconomic status, cultural/spiritual influences, and medical comorbidities. Other limitations of the current analysis relate to its relatively small sample size, which precluded any meaningful subset analysis. The relatively short follow-up period of the current study, coupled with the relatively low survey response rates at the longest follow-up period of 24 months (50% for the UW-QOL and 35% for the FACT-HN surveys) are 2 further limitations. Given that some factors related to long-term QOL, including dysphagia, may manifest many years after treatment, longer follow-up for a greater percentage of patients in the current study will be helpful to evaluate this treatment strategy more fully. Moreover, the current study did not have a control arm receiving full-dose chemoradiation. Therefore, comparisons of patient-reported outcomes between the conventional regimen and the 2 dose de-escalated arms herein could not be performed. As a result, interpretation of the study data was limited to indirect comparison with previous studies of full-dose chemoradiation, resulting in the potential for biases inherent from comparisons with historical data. In addition, it has been established that discrepancies can exist between patientreported and physician-reported QOL outcomes. 25 Last, the possibility of participant bias needs to be acknowledged in that subjects who enrolled on this clinical trial may have possessed certain traits that predisposed them toward improved QOL. It is worth noting that survey completion waned over time. This likely was due to inconsistent delivery of the instruments by study staff, insufficient time for completion at the time of the visit, inconsistent adherence to follow-up encounters, and patient refusal, especially given the relatively long length of both surveys.
The findings of the current study provide what to the best of our knowledge is the first evidence demonstrating that de-escalated chemoradiation administered to patients with HPV-associated oropharyngeal carcinoma leads to improved QOL outcomes compared with historical controls treated with more intensive regimens using standard radiation doses. Although the current study findings largely demonstrate that the use of reduced doses of radiation for patients with HPV-associated oropharyngeal carcinoma indeed translates into tangible benefits with respect to functioning and QOL, they will require validation from other ongoing de-escalation trials.
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